Prabhavathi Fernandes net worth and biography

Prabhavathi Fernandes Biography and Net Worth

Director of Ocugen

Dr. Prabhavathi Fernandes, Ph.D., has more than 35 years of pharmaceutical discovery, development and management experience having held executive leadership positions at pharmaceutical corporations including Bristol-Myers Squibb Pharmaceutical Research Institute, Abbott Laboratories and The Squibb Institute for Medical Research. After leaving Bristol- Myers Squibb, she has founded and led four biotechnology and CRO companies as President, Chief Executive Officer and Director of each of these companies, including Cempra, Inc., DarPharma, Ricerca and Small Molecule Therapeutics. Dr. Fernandes is the Chairperson of both the National Biodefense Science Board (NBSB) and the Scientific Advisory Committee of the Global Antibiotic Research and Development Partnership, a DNDi/WHO initiative. She has also served as an advisor to the World Health Organization. She currently serves on the Boards of OpGen and Aelin Therapeutics. She has authored over 250 publications and several reviews, book chapters and served as an editor for books. Dr. Fernandes obtained her undergraduate and Master’s degree training in India, worked at the University of Ghent, Belgium in Immunochemistry, received her Ph.D. in Microbiology from Thomas Jefferson University, Philadelphia.

What is Prabhavathi Fernandes' net worth?: The estimated net worth of Prabhavathi Fernandes is at least $7,995.00 as of November 26th, 2024. Dr. Fernandes owns 10,000 shares of Ocugen stock worth more than $7,995 as of March 30th. This net worth estimate does not reflect any other investments that Dr. Fernandes may own. Learn More about Prabhavathi Fernandes' net worth.
How do I contact Prabhavathi Fernandes?: The corporate mailing address for Dr. Fernandes and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at ir@ocugen.com. Learn More on Prabhavathi Fernandes' contact information.
Has Prabhavathi Fernandes been buying or selling shares of Ocugen?: Prabhavathi Fernandes has not been actively trading shares of Ocugen during the last ninety days. Most recently, on Tuesday, November 26th, Prabhavathi Fernandes bought 10,000 shares of Ocugen stock. The stock was acquired at an average cost of $0.91 per share, with a total value of $9,100.00. Following the completion of the transaction, the director now directly owns 10,000 shares of the company's stock, valued at $9,100. Learn More on Prabhavathi Fernandes' trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.
Are insiders buying or selling shares of Ocugen?: In the last twelve months, Ocugen insiders bought shares 1 times. They purchased a total of 10,000 shares worth more than $9,100.00. The most recent insider tranaction occured on November, 26th when Director Prabhavathi Fernandes bought 10,000 shares worth more than $9,100.00. Insiders at Ocugen own 4.3% of the company. Learn More about insider trades at Ocugen.
Information on this page was last updated on 11/26/2024.

Prabhavathi Fernandes Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/26/2024	Buy	10,000	$0.91	$9,100.00	10,000
5/25/2021	Sell	33,500	$8.20	$274,700.00	19,500

Prabhavathi Fernandes Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $0.80

$0.70

$0.80

50 Day Range

MA: $0.67

$0.52

$0.80

2 Week Range

Now: $0.80

$0.52

$2.08

Volume

7,023,820 shs

Average Volume

5,099,196 shs

Market Capitalization

$233.47 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.88